RESULTS FROM THE PHASE 3 NORTHSTAR-3 STUDY EVALUATING LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT ß-THALASSAEMIA AND A ß0 OR IVS-I-110 MUTATION AT BOTH ALLELES OF THE HBB GENE.

HemaSphere

A. E. Kulozik, F. Locatelli, E. Yannaki, J. B. Porter, I. Thuret, M. G. Sauer, A. Lal, J. L. Kwiatkowski, H. Elliot, G. Tao, R. A. Colvin, A. A. Thompson. RESULTS FROM THE PHASE 3 NORTHSTAR-3 STUDY EVALUATING LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT ß-THALASSAEMIA AND A ß0 OR IVS-I-110 MUTATION AT BOTH ALLELES OF THE HBB GENE. HemaSphere. 2019 Jun 1; 3:21-22.

2019

https://researcherprofiles.org/profile/79296241

A. E. Kulozik, F. Locatelli, E. Yannaki, J. B. Porter, I. Thuret, M. G. Sauer, A. Lal, J. L. Kwiatkowski, H. Elliot, G. Tao, R. A. Colvin, A. A. Thompson

Northern California Comprehensive Thalassemia Center

Search form

You are here

RESULTS FROM THE PHASE 3 NORTHSTAR-3 STUDY EVALUATING LENTIGLOBIN GENE THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT ß-THALASSAEMIA AND A ß0 OR IVS-I-110 MUTATION AT BOTH ALLELES OF THE HBB GENE.